A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)



Status:Terminated
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - Any
Updated:5/12/2017
Start Date:December 2006
End Date:April 2015

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment

This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in
combination with methotrexate in patients with active rheumatoid arthritis who have had an
inadequate response to methotrexate. Patients will be randomized to receive placebo, 200mg
of intravenous ocrelizumab or 500mg of i.v. ocrelizumab on Days 1 and 15. A repeat course of
i.v. treatment will be administered at Weeks 24 and 26. All patients will receive 7.5mg -
25mg/week concomitant methotrexate at a stable dose. The anticipated time on study treatment
is 1-2 years. Target sample size is 1000.


Inclusion criteria:

- Adult patients, ≥18 years of age

- Rheumatoid arthritis for ≥ 3 months

- Inadequate clinical response to methotrexate at a dose of 7.5-25mg/week for ≥ 12
weeks

Exclusion criteria:

- Rheumatic autoimmune disease or inflammatory joint disease, other than RA

- Prior receipt of any biologic therapy for RA

- Concurrent treatment with any DMARD (other than methotrexate)
We found this trial at
1
site
Trial Information Support Line
South San Francisco, California
?
mi
from
South San Francisco, CA
Click here to add this to my saved trials